Ceftazidime

C difficile risk
High
Oral Bioavailability
N/A

Dosing

  • Pneumonia & other severe infections: 2 gm q8 hours

  • Mild-moderate infections: 1 gm q8 hours

CrCl 0 - 14CrCl 15 - 30CrCl 30 - 50CrCl > 50

  • Severe infections: 2 gm q48 h

  • Mild-moderate infections: 1 gm q48 h

  • Severe infections: 2 gm q24 h

  • Mild-moderate infections: 1 gm q24 h

  • Severe infections: 2 gm q12 h

  • Mild-moderate infections: 1 gm q12 hSame as usual adult dosing

  • Severe infections: 1 gm q24 h

  • Mild-moderate infections: 500 mg q12 h

  • Dose after HD on dialysis days

Varies based on type of CRRT used

General Information

Broad gram negative coverage including Pseudomonas, generally used for nosocomial infections including post-neurosurgical meningitis, or other infections based on susceptibilities.

Notable lack of gram positive activity versus other cephalosporins.

Often used for nosocomial infections where psuedomonas aeruginosa is a consideration

Allergy (immediate and delayed).

Note potential cross-reactivity with aztreonam based on side chain.

Concurrent use of CEFTAZIDIME and WARFARIN may result in an increased risk of bleeding

Antimicrobial class: 3rd generation Cephalosporin

Pregnancy category: B

Average serum half life: 1-2 hours (prolonged in renal impairment)

Biliary penetration: Moderate

CSF penetration: Therapeutic

Lung penetration: Therapeutic

Urine penetration: Therapeutic

Route of Elimination: Urine (80% to 90% as unchanged drug)

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.